Through a combination of in silico modelling, in vitro biochemical, cellular-based assays and in vivo validation, we demonstrate the applicability of this targeted DNMT1-specific platform—aptaDiR, as the first of its kind RNA-based approach to correct aberrant DNA methylation that holds promise for the treatment of cancer or other diseases characterized by aberrant DNA methylation. The gene discussed is DNMT1; the disease is cancer.